10:58 AM EDT, 06/30/2025 (MT Newswires) -- Intensity Therapeutics ( INTS ) said Monday its investigational product candidate, INT230-6, achieved a 100% complete response rate in preclinical models of malignant peripheral nerve sheath tumors in a study at Johns Hopkins University.

At 21 days, animals tested with the drug candidate achieved a complete response, while all the animals' tumors in the control group continued to grow, the company said.

"We look forward to conducting further preclinical research with the Staedtke-Bai laboratory in other neurological cancer models," Intensity President and CEO Lewis Bender said.

Price: 0.31, Change: -0.01, Percent Change: -2.50